The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Continuing high dose clopidogrel treatment after elective PCI decreased adverse cardiac events in patients with clopidogrel resistance

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bursa Postgraduate Hospital
• Treatments: Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

• The patients; who have planned elective PCI and have had written informed consent for participation to study.

• Age>18 year-old,

• The native coronary artery;lesion with narrowing >=70%

Exclusion Criteria:

• Patients have allergy for ASA, Clopidogrel and heparin

• Patients who performed primary PCI

• Patients with acute coronary syndrome

• Patients with have a history of PCI and use clopidogrel

• Patients on warfarin therapy

• Patients who have bleeding diathesis, or have high risk for bleeding.